Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 105Gastrointestinal 56Breast 27Sarcoma 20Gynecologic 19Head & Neck 18CNS 11Endocrine 8Other solid neoplasm 7Tumor-Agnostic 6Genitourinary 5NET 2Dermatologic 2

Conditions

Neuroendocrine Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Digestive System Neoplasms 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
anlotinib × NET × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

NCT03457844 2018-09-11

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumor G3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡